# M2D8: Cell viability, quantitative PCR, 

 identification of regulatory motifs1. Treat cells with DNA damaging agents and inhibitors for cell viability
2. Analyze qPCR results
3. R: Identify regulatory motifs in RNA-seq data

## Extra (+ usual) Office Hours Next Week

- Tuesday April $17^{\text {th }} 56-322$ (lab):
- 10:30am-1:30pm (Leslie)
- 2:00pm-5:00pm (Noreen + Josephine's regular hour)
- Wednesday April 18 ${ }^{\text {th }}$ 56-322 (lab):
- 10:00am-1:00pm (Josephine)
- 2:00pm-4:00pm (Noreen) 4-5pm (Leslie)
- Thursday April 19 ${ }^{\text {th }}$ (56-341c), 10-11am (Josephine)
- Friday April $20^{\text {th }}$ (56-341c), 4-5pm (Leslie)


## Mod2 Research Report (20\% of final grade)

Due Saturday $4 / 21$ at 10 pm

- Title, Abstract
- Introduction
- Methods
- Results (Figures and captions)
- Discussion
- References


## Last week of Mod2!



DAY 4: Evaluate altered gene expression
DAY 5: Investigate public databases
DAY 8: Identify regulatory motifs


DAY 9

## Etoposide is a drug/chemotherapy that causes DNA double strand breaks

- Mechanism of action: forms ternary complex with DNA and topoisomerase II enzyme, prevents re-ligation of the DNA strands
- Cancer cells (quickly dividing cells) rely on topoisomerase II more than normal cells

Topo Type II = topoisomerase II enzyme


Ma, J. \& Wang, M.D. Biophys Rev (2016) 8(Suppl 1): 75. https://doi.org/10.1007/s12551-016-0215-9

Measuring synthetic lethality in our parental and BRCA2-/- cell line

What is synthetic lethality?
combination of deficiencies (eg. knockout, LOF, drug) in 2 or more genes resulting in cell death. One deficiency alone does not cause death
What parallel pathways are we perturbing in this experiment?

$$
\begin{aligned}
& \text { DSB } \rightarrow H R \text { (BRCA2-1-) } \\
& \text { NHEJ (Loperamide, Mibifradil) }
\end{aligned}
$$

What is the result we will assess?
cell viability: cell titer glo-measures ATP via luminescence

## Six compounds identified that target

 NHEJ and / or HR $\quad=$ =amson ac ctracel $0=$ total loss ofRepair activity activity

|  | Repair activity |  |
| :--- | :--- | :--- |
| Drug name | NHEJ | HR |
| Pimozide | 0.28 | 0.55 |
| Loperamide | 0.20 | 0.57 |
| $\rightarrow$ Mibefradil | 0.28 | 0.57 |
| Etoposide | 0.65 | 0.08 |
| SR 59230A | 0.27 | 0.58 |
| AMNO82 | 0.19 | 0.92 |

- Loperamide = slows contractions of intestines, treatment for gastrointestinal ailments
- Mibefradil = blocks calcium channels, treatment for heart conditions


## Synthetic lethality part 1: experiment overview

1. Choose miberfradil or loperamide, sign up at front bench
2. Induce double strand breaks (etoposide $37^{\circ} \mathrm{C}$ for 60 min )
3. Remove etoposide media and incubate with appropriate concentration of miberfradil or loperamide till M2D9


## qPCR (quantitative PCR) is used to detect and quantitate gene expression

- Fluorescence is a function of dSDNA concentration via SYBR green dye
- Initial DNA concentrations are proportional to RNA purified from cells (from which we made cDNA)
- We can compare expression of a particular gene in different conditions by measuring the abundance of the gene-specific transcript
- Expression of the gene of interest is normalized to a housekeeping gene, $\qquad$ GAPDH



## Calculate relative amounts of cDNA based on threshold cycle ( $\mathrm{C}_{\mathrm{T}}$ )

Calculate relative amounts of cDNA based on threshold cycle ( $\mathrm{C}_{\mathrm{T}}$ )
Goal: Find relative expression of p21 to GAPDH $=\frac{[\mathrm{p} 21 \mathrm{mRNA}]}{[\text { GAPDH mRNA }]}=\frac{[\mathrm{p} 21 \mathrm{cDNA}]_{0}^{2}}{[\mathrm{GAPDH} \mathrm{cDNA}]_{0}}$
CDNA concentration
Assuming perfect exponential amplification during each cycle of PCR:
${ }^{y}[\mathrm{p} 21]=[\mathrm{p} 21]_{0} * 2^{\text {cycle\# }}$
$[$ GAPDH $]=[\text { GAPDH }]_{0} * 2^{\text {Cycle\# }}$

- Fluopercence $\alpha$ [dSDNA]
at $G_{T},\left.\quad[P 21]\right|_{G P 21}=\left.[$ GAPDH $]\right|_{C T G A P D H}$
- ©CT, $\approx$ fixed [dSDNA]

$$
\begin{aligned}
{[\text { P2I }]_{0} \times 2^{C_{T P 21}} } & =[\text { GAPDH }]_{0} \times 2^{\text {GGAPDH }} \\
\downarrow & {[\text { [P21 CDNA }]_{0} } \\
{[\text { GAPDH CDNA }]_{0} } & =2^{\left(C_{\text {TGIPDH }}-C_{\text {TP21 }}\right)}=2^{-\left(C_{\text {TPLI }}-C_{\text {TGAPDH }}\right)}
\end{aligned}
$$ assuming similar lengths

# qPCR melt curve indicates the number of dsDNA products in reaction 

Negative derivative of fluorescence vs. temperature


What would cause multiple peaks?
multiple products
$\rightarrow$ primers created off-farget product, sequence similar
$\rightarrow$ accidentally put multiple primer pairs for different genes in same well
$\rightarrow$ Splice variants

## Computational exercise—transcription factor binding site motifs

- Calculate position weight matrices
- Search public database of transcription factor binding
- Scan sequences to look for matching motifs
- Practice expectation-maximization algorithm for de novo motif discovery



## Today in lab

1. Drug treat cells in tissue culture:
$-\quad 1^{\text {st }}:$ Pink, Purple, Platinum

- $\quad 2^{\text {nd }}$ :Red, Orange, Green, Blue

2. Analyze qPCR data
3. Complete "Transcription Factor Motifs" R exercise

HW due M2D9:

- Create figure of qPCR analysis with related RNA seq data (plot of p21 expression in various conditions), including figure title and caption
- Associated results section
- Associated discussion section

